One biotech is proposing incremental payments for its experimental gene therapy, a drug expected to carry a roughly seven-figure price tag.
According to a Wall Street Journal report, Bluebird Bio Inc. is mulling a new payment strategy for the innovative drug to treat a rare inherited blood disease. The company is considering a five-year payment plan, with each annual payment hinging on the drug’s effectiveness.
To read the full report on the Wall Street Journal, click here. (Paid subscription required).